TRUL:CA:CNSX-Trulieve Cannabis Corp (CAD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | CNSX

Last Closing Price

CAD 32.42

Change

0.00 (0.00)%

Market Cap

CAD 6.00B

Volume

0.20M

Avg Analyst Target

CAD 77.00 (+137.51%)

Avg User Target

CAD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of August 25, 2021, the company operated 100 dispensaries, which include 90 locations in Florida. Trulieve Cannabis Corp. has a strategic partnership with SLANG Worldwide Inc. to supply branded cannabis products in Massachusetts. The company is headquartered in Quincy, Florida. Address: 6749 Ben Bostic Road, Quincy, FL, United States, 32351

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-16 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
CURA:CA Curaleaf Holdings Inc

N/A

CAD9.22B N/A 39.35
GTII:CA Green Thumb Industries Inc

N/A

CAD6.53B 80.25 24.48
CL:CA Cresco Labs Inc

N/A

CAD2.65B N/A 18.82
HARV:CA Harvest Health & Recreation In..

N/A

CAD1.65B N/A 122.88
VRNO:CA Verano Holdings Corp

N/A

CAD1.64B 20.03 26.99
AYR-A:CA Ayr Wellness Inc

N/A

CAD1.63B N/A N/A
CCHW:CA Columbia Care Inc

N/A

CAD1.55B N/A 147.88
TER:CA TerrAscend Corp

N/A

CAD1.35B N/A N/A
PLTH:CA Planet 13 Holdings Inc

N/A

CAD1.02B N/A 75.43
FFNT:CA 4Front Ventures Corp

N/A

CAD0.92B N/A N/A

ETFs Containing TRUL:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 6.00B 98% A+ 100% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 36.10 26% F 19% F
Price/Book Ratio 4.52 30% F 39% F
Price / Cash Flow Ratio 60.25 4% F 3% F
EV/EBITDA 22.78 47% F 34% F
Management Effectiveness  
Return on Equity 17.05% 97% A+ 95% A
Return on Invested Capital 28.11% 90% A- 85% B
Return on Assets 19.21% 98% A+ 99% A+
Debt to Equity Ratio 0.89% 74% C 55% F
Technical Ratios  
Short Ratio 10.41 2% F 2% F
Short Percent 2.36% 1% F 1% F
Beta 1.33 57% F 49% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.